Biotechnology Business Investment Opportunities

Our brand is the world’s first instant methanol detection test, designed to protect consumers from deadly counterfeit alcohol. Our rapid-detection strip provides a fast, portable, and affordable solution for travelers, bars, hotels, and government agencies. HQ: Planned Dubai launch for cost-effective operations, global scalability, and safety of transactions. Market opportunity: $60B+ counterfeit alcohol crisis worldwide (1,000s of people die from methanol poisoning each year! and there is no way to test the drinks) Revenue model: • Direct-to-consumer (DTC): Sold online (Amazon, TikTok Shop, website) through major online retailers worldwide. • Bulk B2B sales: Hotels, universities, hospitals, pharmacies, retailers, train stations, bars, duty-free retailers. Globally. • Licensing deals: Partnering with biotech firms & alcohol brands for distribution. Projected price: ~$19.99 per pack, we must aim to have a 70% margin. Projected sales growth: •Year 1: 50K units → $1M revenue. •Year 2: 250K units → $5M revenue. •Year 3: 1M+ units → $20M+ revenue. Exit strategy: Sell to a biotech or alcohol safety giant etc for $50M+ or license the technology for passive royalties. Promoter experience & business relationships: • Founder: Experienced entrepreneur with expertise in luxury branding, viral marketing, and scaling consumer products with the globally recognized superstars behind the previous brand I have developed. • Scientific & business team: Partnering with chemists & biotech advisors to ensure product reliability. • Distribution talks: Engaging bars, airlines, hotels, etc. • Investor network: Seeking 1-2 strategic investors to fund final development and global launch. This product is positioned to disrupt a billion-dollar problem and scale as the go-to alcohol safety brand worldwide. Some of the brightest minds in biotech and science will be on board. The product is not medicine and does not need to be FDA-approved as we will market it as a consumer product (like pregnancy tests). The product will deliver a 90% accuracy which is enough to save millions of lives. This is a once-in-a-lifetime opportunity and we are applying for patents already.

Situated in Fremont, this business specializes in manufacturing assay kits for biochemicals, enzymes, and ions, serving primarily the life science and biotechnology sectors. - The company focuses on providing research products that are designed to be user-friendly, highly reproducible, and cost-effective, potentially advancing research in serious health conditions such as cancer, diabetes, and neurodegenerative diseases. - With a global network of 30-35 distributors, the company exports 90% of its products mainly to European and Asian markets, including key countries like China, Korea, and Japan. - The production capacity stands at manufacturing 500 kits per day, ensuring steady supply capabilities to meet the needs of international research communities. - Orders are fulfilled on a weekly basis, facilitating consistent supply and robust support for ongoing research projects worldwide. - The business is not yet profitable, as its revenue is being reinvested into expansion and growth efforts. - By focusing on quality and affordability, the company distinguishes itself as a competitive player in the assay kit market, supporting vital research across continents.

The company is strategically positioned in the biotechnology sector, with plans to specialize in high-demand services such as flow cytometry and cell culture, tailored to support pharmaceutical, biotech, and diagnostic companies. - Despite being registered 4 years ago, the company has yet to start operations but has laid the groundwork through strategic collaborations and grant submissions totalling approximately USD 40 million, showcasing a strong potential for funding acquisition. - The promoter's extensive background, with a PhD in cell biology and two decades of research experience, provides a strong foundation for the company's technical expertise and leadership. - Possession of distribution rights for crucial research kits and therapeutic proteins indicates early-stage readiness to supply essential products to the research community. - The company maintains strategic collaborations with antibody-based firms, enhancing its capability to provide comprehensive solutions for advanced therapeutic and research needs. - Haverhill, the company's location, provides access to a strategic geographical position that can facilitate partnerships with key biotech and pharmaceutical players. - The planned service offerings, including advanced flow cytometry and specialized cell culture services, underscore the company's commitment to supporting cutting-edge research with reliable and customizable solutions.

Planning to establish a cannabis plantation to produce anesthetic drugs. - Seeking foreign investors to comply with the local law, which mandates that only foreigners can hold a license for cannabis plantations. - The promoter is an Ayurvedic doctor with 30 years of experience in the industry. - We will be applying for licenses, and only foreigners are eligible to hold them. - Our plan is to establish a cannabis plantation and export cannabis anesthetic drugs through distributors worldwide. - The drugs will be specifically formulated for anesthesia purposes.

An AI-enhanced physics-based drug discovery company. - Integrates artificial intelligence, computational chemistry, and peptide science to expedite therapeutic compound discovery and optimize leads. - Discovers and optimizes active, specific, non-toxic, and patentable small molecules delivering superior drug candidates. - The company boasts a diverse clientele, with more than 6 clients including reputable organizations such as Deloitte Belgium, B. Braun, Fresenius Kabi, and UCB Pharma. - The company currently generates revenue through the provision of management consulting services for pharmaceutical and biotech companies. It operates on a per-service-based charging model. - Company is currently engaged in the development of brain-specific and selective butyrylcholinesterase inhibitors for the treatment of severe Alzheimer's. - The business is not yet profitable as it is reinvesting its revenue into research and development activities, - The company has 2 additional contract employees for R&D activities.

High potential company with a science-proven, patented beverage for acute alcohol intoxication. - Our product is a science-based beverage designed for the resolution of acute alcohol toxicity. - The company has developed this product over the past 3 years and is now seeking early-stage investors to bring it to market. - We are in discussions with approximately 18 major clients in the pharmaceutical industry, including pharma product buyers and large pharmacies such as Audifarma and Eticos Serrano, to ensure effective product introduction and distribution. - Our team has over 4 years of successful experience in launching pharmaceutical products in the Colombian market. - We will be available in the market in the next few months. - Our target audience is the alcohol consumption market, focusing on providing a solution for alcohol elimination in intoxicated individuals. - The company is currently in the pre-seed stage. - We are planning to establish a manufacturing unit soon, with a production capacity of 100,000 units per month. - Company has incorporation license and INVIMA registration (license from the National Food and Drug Surveillance Institute)

The company is a bio-medical startup based in Mumbai with a current manufacturing capacity of 20,000 units and is seeking investment to scale marketing, distribution, and assembly. - The heart rate monitor is the top-selling product, with an average of 200 units sold per month through online channels such as the company's website and Amazon. Revenue sources are diversified, with 40% of sales revenue coming from Amazon and 60% from the company's website. The company utilizes Ship Rocket and Amazon for logistics. - The company's current sales are entirely business-to-consumer (B2C) - The company has garnered interest from Bridge Health and Fitterfly for the use of its product in BP reduction programs, showcasing the potential for further B2B partnerships. - The heart rate monitor is currently sold at an introductory price of INR 1,999 for the first 1,000 devices, with the regular price set at INR 3,499. The company aims to sell approximately 1 lakh units by the end of the year. - The product current has a +/- 2 points tolerance, which shows they are 98% accurate. - Collaborating with telemedicine doctors. - The company has currently outsourced manufacturing with a manufacturing capacity of approximately 20,000 units manufactured a month and we have our own testing and assembly rigs to avoid any leaking of design and work. - The business already has a ready stock of more than 10,000 units in inventory and is sending them for testing to its partners. - The business holds the necessary GST certificate & an ISO 13485 certificate.

A biotech firm based in Milan, focusing on cancer immuno personalized therapy. - Has a portfolio of R&D projects and two Finished Dosage Forms (FDF) in the Italian market, including Aripiprazole and Emtricitabine + Tenofovir. - The company specializes in the development of microfluidic technology for the production and purification of Exosomes, with applications in anti-inflammatory, skin regenerative, anti-acne and atopic dermatitis, scalp rejuvenation, and hair growth treatments. - Exosomes, a key product of the company, are body-identical ingredients known for their high stability and low likelihood of causing adverse reactions. Their cell-penetrating mechanism enables them to deliver regeneration signals, making them suitable for diverse medical and cosmetic applications. - Has 3 major clients and supplied on a quarterly basis to pharmaceutical companies in Italy, Poland, and Brazil. - Operates with a network of 12 agents in addition to its 3 permanent employees. - Collaborates with Contract Manufacturing Organizations (CMOs) for the production of its pharmaceutical products. The company holds essential regulatory licenses from GMP, FDA, and the Ministry of Health, ensuring compliance with international quality and safety standards.

Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI. - Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells. - Has patented and licensed technologies from premier research institutions. - The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception. - The company is currently engaged in a gene therapy research project involving 2,600 samples. - There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.

Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing. - Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process. - A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions. - Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine. - Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept. - Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc. - Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients. - Positioned in the $300 billion back pain industry, addressing a significant market need. - Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development. - Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility. - Founded by individuals with decades of experience in the industry.

• Healthcare business located in the United Kingdom offering gene therapy products and services. • University spin-out with patented technology and other scientific developments in the pipeline. • Aiming to improve the safety and efficiency of gene therapy. • Top selling products will be tests to ascertain if a person can repair their DNA, testing if a virus used to deliver a gene therapy will actually be safe. • Gene therapy and CAR-T therapy is a rapidly growing field, offering great potential for the company. • Experienced team of scientists and engineers ready to create a successful business. The business is not operational currently. • Unique products and services that can be marketed to potential customers worldwide.